Pharmacokinetics/pharmacodynamics (PK/PD) approach in the veterinary medicine

被引:0
|
作者
Somogyi Zoltan [1 ]
Karancsi Zita [1 ]
Jerzsele Akos [1 ]
机构
[1] ATE Gyagyszertani & Meregtani Tanszek, Szeged, Hungary
关键词
PHARMACOKINETICS; FLORFENICOL; DOXYCYCLINE;
D O I
暂无
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Among veterinary drugs, antibacterial drugs are frequently used in the clinical practice. The aim of antibacterial therapy is to enhance clinical outcome and eliminate pathogenic microbes. Antibacterial pharmacokinetic/pharmacodynamic (PK/PD) relationship reflects a correlation between the antibacterial drug concentration in the blood, the concentration of biologically active drug at the site of the infection, and the sensitivity of the microbe. The PK parameters, such as AUC and C-max, describe the fate of the drug in the host. The PD parameters, such as MIC, describe the inhibitory effect of the drug on bacterial pathogens. The three most frequently used PK/PD indices are ratio of area under the concentration time curve at 24 h to the MIC (AUC(0-24)/MIC), the ratio of the peak drug concentration to the MIC (C-max/MIC), and the percentage of the dosing interval for which the plasma concentration exceeds the MIC (%T > MIC). Using of PK/PD approach in veterinary medicine can optimize the right dosing regimen. Therefore, reduced toxicity and reduction in the incidence of resistance are important consequences. The emergence of resistance is a global issue in human and veterinary medicine alike. The aim of this review is to introduce PK/PD relationships in veterinary medicine based on in vitro and in vivo models.
引用
收藏
页码:37 / 46
页数:10
相关论文
共 50 条
  • [41] Analysis of pharmacokinetics and PK/PD parameter Cmax/MIC for ciprofloxacin in patients with neutropenic fever
    Szalek, Edyta
    Kaminska, Agnieszka
    Lojko, Anna
    Grzeskowiak, Edmund
    Komarnicki, Mieczyslaw
    Murawa, Dawid
    Nabywaniec, Katarzyna
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2010, 14 (04): : 286 - 290
  • [42] Functional Biomarkers: an Approach to Bridge Pharmacokinetics and Pharmacodynamics in Pediatric Clinical Trials
    Kearns, Gregory L.
    Artman, Michael
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (39) : 5636 - 5642
  • [43] Pharmacokinetics and Pharmacodynamics of Inhaled Glucocorticoids
    Padden, Jennifer
    Skoner, David
    Hochhaus, Gunther
    JOURNAL OF ASTHMA, 2008, 45 (10) : 13 - 24
  • [44] Metformin pathways: pharmacokinetics and pharmacodynamics
    Gong, Li
    Goswami, Srijib
    Giacomini, Kathleen M.
    Altman, Russ B.
    Klein, Teri E.
    PHARMACOGENETICS AND GENOMICS, 2012, 22 (11) : 820 - 827
  • [45] EFFECT OF CHIRALITY ON PHARMACOKINETICS AND PHARMACODYNAMICS
    CROM, WR
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1992, 49 (09): : S9 - S14
  • [46] PHARMACOKINETICS AND PHARMACODYNAMICS OF METRIFONATE IN HUMANS
    UNNI, LK
    WOMACK, C
    HANNANT, ME
    BECKER, RE
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1994, 16 (04): : 285 - 289
  • [47] Gender differences in pharmacokinetics and pharmacodynamics
    Beierle, I
    Meibohm, B
    Derendorf, H
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1999, 37 (11) : 529 - 547
  • [48] The pharmacodynamics and pharmacokinetics of mivacurium in children
    Ostergaard, D
    Gätke, MR
    Berg, H
    Rasmussen, SN
    Viby-Mogensen, J
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2002, 46 (05) : 512 - 518
  • [49] Volterra series in pharmacokinetics and pharmacodynamics
    Verotta, D
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2003, 30 (05) : 337 - 362
  • [50] Predicting the pharmacokinetics and pharmacodynamics of antisense oligonucleotides: an overview of various approaches and opportunities for PBPK/PD modelling
    Gao, Xiang
    Diep, John K.
    Norris, Daniel A.
    Yu, Rosie Z.
    Geary, Richard S.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2023, 19 (12) : 979 - 990